PI
NTGN

Pharmstandard International’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Pharmstandard International’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5.03M Buy
+588,611
New +$6.52M 17.31% 3

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PIM
Partner Investment Management San Francisco, California $13.9M AUM 55.92% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Pharmstandard International's NTGN Position: Q3 2018 in Review

Pharmstandard International opened a new position in Neon Therapeutics, Inc. Common Stock (NTGN) in Q3 2018: 588,611 shares worth $5.03M. The stake represents 17.31% of the portfolio and ranks #3 among its holdings.

45 funds tracked by Wall St. Rank hold NTGN as of Q3 2018.

  • Pharmstandard International held 588,611 shares of Neon Therapeutics, Inc. Common Stock worth $5.03M as of Q3 2018.
  • Neon Therapeutics, Inc. Common Stock was a new Pharmstandard International position in Q3 2018.
  • Neon Therapeutics, Inc. Common Stock made up 17.31% of Pharmstandard International's portfolio in Q3 2018, its #3 holding.
  • 45 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Pharmstandard International's 13F filing for Q3 2018, filed 15 Nov 2018.